J Cancer 2023; 14(2):183-192. doi:10.7150/jca.78599 This issue Cite

Review

Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics

Zita Képes, György Trencsényi

Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.

Citation:
Képes Z, Trencsényi G. Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics. J Cancer 2023; 14(2):183-192. doi:10.7150/jca.78599. https://www.jcancer.org/v14p0183.htm
Other styles

File import instruction

Abstract

Graphic abstract

Since metastases are responsible for the majority of cancer-related death, in-depth understanding of metastatisation may provide an opportunity for the introduction of new therapeutic as well as diagnostic approaches in cancer management. Previously, preclinical research into the development and progression of malignancies has been hampered by the relative paucity of in vivo tumor models. Subrenal capsule assay (SRCA)-induced tumor-bearing experimental animal models, however, serve as potential preclinical model systems for the assessment of primary tumors and the route of metastatic spread. Several studies implementing either Hepatocarcinoma (He/De), Mesoblastic Nephroma (Ne/De), chemically induced Myeloid Leukemia (My1/De), or spontaneous Myeloid Myelomonocytic Leukemia (My2/De) cells under the left renal capsule of rats applying SRCA method were underway to study secondary tumor formation. Based on the results of this research, subrenally transplanted neoplastic cells led to the appearance of metastasis in the parathymic lymph nodes. Therefore, renal capsule/parathymic lymph node complex seems to be valuable in the in vivo evaluation of the process of metastatisation and the occurrence of secondary neoplasms. The re-emergence of this highly promising SRCA-based renal capsule/parathymic lymph node complex in preclinical nuclear medicine and experimental oncology may open a novel field towards drug trials and radiopharmaceutical development. In the present review, we provide a detailed overview of the history of SRCA as well as the series of research on the establishment of renal capsule/parathymic lymph node complex.

Keywords: Metastasis, Parathymic Lymph Node, Positron Emission Tomography, Subrenal Capsule Assay, Transplantation, Tumorigenesis


Citation styles

APA
Képes, Z., Trencsényi, G. (2023). Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics. Journal of Cancer, 14(2), 183-192. https://doi.org/10.7150/jca.78599.

ACS
Képes, Z.; Trencsényi, G. Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics. J. Cancer 2023, 14 (2), 183-192. DOI: 10.7150/jca.78599.

NLM
Képes Z, Trencsényi G. Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics. J Cancer 2023; 14(2):183-192. doi:10.7150/jca.78599. https://www.jcancer.org/v14p0183.htm

CSE
Képes Z, Trencsényi G. 2023. Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics. J Cancer. 14(2):183-192.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image